We are a privately held clinical-stage biotechnology company focusing on the development and commercialization of a revolutionary new immune therapy technology platform for the treatment of chronic viral infections, cancer and allergy. Our Immune Therapies are designed to boost specific immune response in order to modify or control presently incurable diseases.
Our proprietary Platform Technology includes an antigen specific plasmid DNA (pDNA) that is encapsulated in a nanomedicine formulation to make it closely resemble a virus, and a topical (through the skin) administration device which delivers the vaccine via dendritic cell to lymph nodes of the immune system. Our technology support the rapid and cost-effective development of original biologic (as opposed to drugs) products.
Our Lead Therapeutic Vaccine for treatment of HIV, referred to as “DermaVir”, is effective in boosting immune response which in turn kills HIV-infected cells. Our human clinical trials in Phase I, Phase I/II and Phase II have demonstrated our vaccine is capable of killing HIV-infected cells. DermaVir has an excellent safety profile similar to vaccines used in healthy adults and children. DermaVir can also be a co-treatment option if administered with antiretroviral therapy.
We are raising funds in an Initial Coin Offering (ICO) to complete the regulatory documentation needed to seek United States Food and Drug Administration (FDA) guidance on the best path to marketing approval, including Breakthrough Therapy Designation and Fast-track.
I just published “Is an HIV treatment paradigm shift possible?” https://t.co/tTof93oIww
— Dermavir (@DermavirICO) February 23, 2018
Post approval our products will allow people to live better and longer lives.
Please visit out website for more information: www.geneticimmunity.com
You can also sign up to our Telegram channel HERE
And register for our Whitelist HERE.
— Dermavir (@DermavirICO) February 25, 2018